Profile of lumacaftor/ivacaftor combination: potential in the treatment of cystic fibrosis

References

• Cystic Fibrosis Foundation. What Is Cystic Fibrosis? 2014. Available from: http://www.cff.org/AboutCF. Accessed June 2, 2015.
   Google Scholar
• O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891–1904.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992–2001.
   PubMed Web of Science ®Google Scholar
• Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest. 2011;139:1480–1490.
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–1073.
   PubMed Web of Science ®Google Scholar
• Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73:1251–1254.
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2013. Available from: http://www.cff.org/Our-Research/CF-Patient-Registry/. Accessed June 2, 2015.
   Google Scholar
• Kalydeco™ (ivacaftor) [Product information]. Cambridge, MA: Vertex Pharmaceuticals Inc.; 2012.
   Google Scholar
• Ramsey BW, Davies J, McElvaney G, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672.
   PubMed Web of Science ®Google Scholar
• Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219–1225.
   PubMed Web of Science ®Google Scholar
• Flume PA, Liou T, Borowitz D, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for F508del-CFTR mutation. Chest. 2012;1:1–50.
   Google Scholar
• Davies JC, Robertson S, Green Y, Rosenfeld M. An open-label study of the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2 to 5 years with CF and CFTR gating mutation: the KIWI study. Poster presented at: The 28th Annual North American Conference of the Cystic Fibrosis Foundation, October 9–11, 2014, Atlanta, GA.
   Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Am Sci U S A. 2011;108(46):18843–18848.
   PubMed Web of Science ®Google Scholar
• Kopeikin Z, Yukesk Z, Yang H, Bompadre SG. Combined effects of VX-770 and VX-809 on several functional abnormalities on F508del-CFTR channels. J Cyst Fibros. 2014;13:508–514.
   PubMed Web of Science ®Google Scholar
• Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67:12–18.
   PubMed Web of Science ®Google Scholar
• Rowe SM, McColley SA, Rietschel E, et al. Effect of 8 weeks of lumacaftor in combination with ivacaftor in patients with CF and heterozygous for the F508del-CFTR mutation. Poster presented at: The 28th Annual North American Conference of the Cystic Fibrosis Foundation, October 9–11, 2014, Atlanta, GA.
   Google Scholar
• Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic fibrosis foundation consensus report. J Pediatr. 2008;153(2):S4–S14.
   PubMed Web of Science ®Google Scholar
• Ramsey B, Boyle MP, Elborn S, et al. Effect of lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for F508del-CFTR: pooled results from the phase 3 TRAFFIC and TRANSPORT studies. Poster presented at: The 28th Annual North American Conference of the Cystic Fibrosis Foundation, October 9–11, 2014, Atlanta, GA.
   Google Scholar
• Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D -CFTR mutation. N Engl J Med. 2010;363:1991–2003.
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Marigowda G, Liu F, Waltz D. Pharmacokinetics and safety of lumacaftor in combination with ivacaftor in patients aged 6–11 years with CF who are homozygous for F508del-CFTR. Poster presented at: The 28th Annual North American Conference of the Cystic Fibrosis Foundation, October 9–11, 2014, Atlanta, GA.
   Google Scholar
• Food and Drug Administration. Clinical Briefing Document for the Pulmonary Allergy Drugs Advisory Committee Meeting. Lumacaftor/Ivacaftor Oral Tablets. Silver Spring, MD: Department of Health and Human Services, Food and Drug Administration; 2015.
   Google Scholar
• Pawaskar D, Marigowda G, Waltz D, et al. The effect of ciprofloxacin, itraconazole, and rifampin on the pharmacokinetics of lumacaftor in combination with ivacaftor in healthy individuals. Poster presented at: The 28th Annual North American Conference of the Cystic Fibrosis Foundation October 9–11, 2014, Atlanta, GA.
   Google Scholar
• Vertex Pharmaceuticals Incorporated. Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation. Boston, MA: Vertex Pharmaceuticals Incorporated. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=912730. Accessed May 12, 2015.
   Google Scholar
• Orkambi™ (lumacaftor/ivacaftor) [Product information]. Boston, MA: Vertex Pharmaceuticals Inc.; 2015.
   Google Scholar
• ClinicalTrials.gov VX661 Studies. Available from: https://www.clinicaltrials.gov/ct2/results?term=VX661&Search=Search. Accessed June 8, 2015.
   Google Scholar